MediWound Revenue Jumps 43% in Q2

MediWound(NASDAQ:MDWD) reported fiscal second quarter 2025 results on Aug. 14, 2025, with revenue rising 43% quarter over quarter to $5.7 million, driven by higher product sales and a favorable mix. The company advanced its Phase III EscharEx VALUE trial, expanded NexoBrid’s U.S. presence, and continued scaling manufacturing to meet global demand. Key strategic partnerships and operational milestones position MediWound for further growth and regulatory progress.During the quarter, MediWound established new collaborations with wound care leaders ConvaTec (LSE:CTEC) and SCT, adding to existing relationships with Solventum (NYSE:SOLV), Mölnlycke, and others. These partnerships now cover all major categories of standard-of-care products integrated into clinical trial protocols, supporting both the ongoing venous leg ulcer (VLU) Phase III trial and the planned diabetic foot ulcer (DFU) trial.This broad network of industry partners reduces adoption risk and positions EscharEx for widespread real-world use, as clinical protocols now reflect the diversity of standard wound care practices across major markets.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool